Why bfri is not going up after fda approval

Biofrontera (BFRI) recently experienced a decline in its stock price from October 2 to October 7, which may be influenced by several factors:

1. Market Reaction to FDA Approval: The market may have already priced in the positive outcome of the FDA approval, leading to a lack of additional positive reaction upon announcement. This is often referred to as a "double bottom" pattern, where the stock price falls back to its pre-approval levels.
2. Limited Market Impact: The FDA approval is likely to have a more significant impact on the future sales and treatment options of Ameluz rather than its immediate market price. The approval is a milestone for Biofrontera, but it might not directly translate to an immediate surge in the stock price due to market dynamics.
3. Broad Market Trends: The overall market conditions, including investor sentiment, geopolitical tensions, and economic indicators, can influence stock prices. For example, the conflict in the Middle East and the labor market surprises may have created a cautious atmosphere, affecting BFRI's stock price even after positive news like the FDA approval.

In conclusion, while the FDA approval is a significant achievement for Biofrontera, it does not necessarily translate to an immediate increase in the stock price, which is influenced by a complex interplay of various market factors.